Biomind Labs will participate in the PSYCH symposium at the National Gallery in London


TORONTO–(BUSINESS WIRE)–Biomind Laboratories Inc. (“Biomind Laboratories“or the”Company”) (NEO: BMND) (OTC: BMNDF) (FSE: 3XI), a leading biotechnology company developing the next generation of pharmaceuticals to treat patients with neurological and psychiatric disorders by scientifically harnessing the medicinal power of molecules psychedelics, is pleased to announce that he will be participating in the “PSYCH Symposium: London 2022 – Unleashing the Potential of Psychedelic Healthcare » which will be held at the National Gallery on Wednesday 11 May 2022.

Alejandro Antalich, CEO of Biomind Labs, commented: “The PSYCH symposium will be one of the most relevant events in the psychedelic industry in 2022, and that’s why we decided to participate in debates with the main leaders of the sector and use this forum to present our future projects.

Last year Prime Minister Boris Johnson said he would consider the latest advice on legalizing a psychedelic drug. We must confess that with this statement, Prime Minister Johnson has earned our respect because as the leader of a nation he has shown empathy towards millions of patients who suffer from any type of health disorder mentality, and that kind of attitude is what world leaders need.

We support Mr. Crispin Blunt’s initiative which has had a positive impact on Prime Minister Johnson, in the hope of promoting global analysis and review of psychedelic legalization by government authorities, regulators and the psychiatric community. As more clinical research needs to be conducted, time is becoming critical for the nearly one billion people affected by mental disorders,” Mr Antalich concluded.

The UK is home to world-renowned psychedelic research institutions, which lay the foundation for a thriving national industry, with the PSYCH Symposium championing the emerging ecosystem. The PSYCH Symposium is a unique experience that enables industry leaders to collaborate to accelerate access to psychedelic healthcare across Europe. As the industry develops, research briefing notes, regulatory updates and topical debates can provide the information and insights needed to navigate this burgeoning landscape, while ensuring a sustainable, patient-focused approach to how the industry defines itself in the future.

About Biomind Labs Inc.

Biomind Labs is a biotechnology research and development company focused on transforming biomedical science knowledge into new pharmaceutical drugs and innovative nanotechnology delivery systems for a variety of psychiatric and neurological conditions. Through its acceleration platform, Biomind Labs develops new pharmaceutical formulations of the main psychedelic molecules, N,N-dimethyltryptamine, 5-MeO-DMT and mescaline to treat a wide range of therapeutic indications. Biomind Labs’ goal is to provide patients with access to affordable and modern treatments.

Caution Regarding Forward-Looking Statements

This press release contains statements that constitute “forward-looking information” (“forward-looking information”) within the meaning of applicable Canadian securities laws. All statements, other than statements of historical facts, are forward-looking information and are based on expectations, estimates and projections as of the date of this press release. Any statement that discusses predictions, expectations, beliefs, plans, projections, goals, assumptions, future events or performance (often but not always

using expressions such as “expects”, or “does not expect”, “is planned”, “anticipates” or “does not anticipate”, “plans”, “budget”, “expected” , “plans”, “believes”, “believes” or “intends” or variations of these words and expressions or indicating that certain actions, events or results “may” or “could”, “would”, “might ” or “will” be expected to occur or be achieved) are not statements of historical fact and may be forward-looking information. Forward-looking statements contained in this document include, among others, statements relating to the Company’s ability to scientifically harness the medicinal power of psychedelic molecules to treat patients with neurological and psychiatric disorders, the possibility of global analysis and ‘a review of psychedelic legalization by government authorities, regulators and the psychiatric community, any statements regarding the future impact of the PSYCH Symposium, the Society’s business plans and growth plans, the burgeoning landscape of the psychedelic industry, and other statements that are not historical facts.

By their nature, forward-looking statements involve known and unknown risks, uncertainties and other factors that may cause our actual results, performance or achievements, or other future events, to be materially different from the results, performance or future achievements expressed or implied by such forward-looking statements. These factors and risks include, among others: (a) the Company may need additional funding from time to time in order to continue its operations which may not be available when needed or on acceptable terms; (b) compliance with extensive government regulation; (c) domestic and foreign laws and regulations could adversely affect the Company’s business and results of operations; (d) stock markets have experienced volatility that has often been unrelated to business performance and such fluctuations may adversely affect the price of the Company’s securities, regardless of its operating peers; (e) adverse changes in public perception of tryptamine treatments and psychedelic therapies; (f) the impact of COVID-19; and (g) general business, economic, competitive, political and social uncertainties. Accordingly, readers should not place undue reliance on the forward-looking information contained in this press release.

The Company makes no medical, treatment or health benefit claims regarding the products offered by the Company. The United States Food and Drug Administration, Health Canada, or other similar regulatory authorities have not evaluated claims regarding tryptamine treatments, psychedelic therapies, or other psychedelic compounds. The effectiveness of these products has not been confirmed by approved research. There is no guarantee that the use of psychedelic tryptamines, tryptamine derivatives, or other psychedelic compounds can diagnose, treat, cure, or prevent any disease or condition. Vigorous scientific research and clinical trials are needed. The Company has not yet completed commercial clinical trials for the use of the products it offers. Any reference to the quality, consistency, efficacy and safety of potential products does not imply that the Company has verified it in commercial clinical trials or that it will complete such trials. Failure of the Company to obtain the necessary approvals or research to commercialize its business could have a material adverse effect on its performance and business.

The forward-looking information contained in this press release represents the Company’s expectations as of the date of this press release and, accordingly, is subject to change after such date. Readers should not place undue importance on forward-looking information and should not rely on such information as of any other date. The Company undertakes no obligation to update these forward-looking statements if management’s beliefs, estimates or opinions, or other factors, should change.

The Neo Exchange Inc. has neither approved nor disapproved of the contents of this press release and is not responsible for the adequacy and accuracy of the contents herein.


About Author

Comments are closed.